

Adult Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (DR-TB '22)	EML submitted	EML (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Amikacin 100mg vial	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	Ineligible for inclusion	
Amikacin 500mg/2mL vial	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Amoxicillin/clavulanate 500mg/125mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Bedaquiline 100mg tablet	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	
Clofazimine 100mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	
Clofazimine 50mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	
Cycloserine 250mg capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Adult Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (DR-TB '22)	EML submitted	EML (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Delamanid 50mg tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Ethambutol 400mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Ethionamide 250mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Gatifloxacin 200mg tablet	No	No	Yes	N/A	Yes	No	No	No	No	Ineligible for inclusion	Ineligible for inclusion	No
Gatifloxacin 400mg tablet	No	No	Yes	N/A	Yes	No	No	No	No	Ineligible for inclusion	Ineligible for inclusion	No
Imipenem/cilastatin 250/250mg vial	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	Yes	No	Ineligible for inclusion	No	No
Imipenem/cilastatin 500/500mg vial	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes

Status
■ Yes
■ No
■ Ineligible for inclusion
■ N/A

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Adult Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (DR-TB '22)	EML submitted	EML (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Imipenem/cilastatin/clavulanate 500/500/125 mg vial	Yes	Yes	No	No	Yes	No	No	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Levofloxacin 250mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Levofloxacin 500mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Levofloxacin 750mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Linezolid 600mg tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Meropenem 1000mg vial	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Adult Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (DR-TB '22)	EML submitted	EML (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Meropenem 500mg vial	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Meropenem/clavulanate 1000 mg/125 mg vial	Yes	Yes	No	No	Yes	No	No	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Moxifloxacin 400mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
PAS 4gm granules	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Ineligible for inclusion	Ineligible for inclusion	No	No
PAS Sodium 4gm/5.52gm powder	Yes	Yes	No	No	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Pretomanid 200mg tablet	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Protionamide 250mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023

Adult Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (DR-TB '22)	EML submitted	EML (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status
Pyrazinamide 400mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Pyrazinamide 500mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Streptomycin 1000mg vial	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Terizidone 250mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Terizidone 500mg tablet	Yes	Yes	No	No	Yes	No	No	No	No	Ineligible for inclusion	Ineligible for inclusion	No

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023